Sponsored Links

BRIEF-Teva Pharm CEO sees 2013 near midpoint of its outlook

Thu Aug 1, 2013 8:32am EDT

Aug 1 (Reuters) - Teva Pharmaceutical Industries Chief Executive Officer said:

* Anticipate to end the year near the midpoint of annual guidance

* Teva previously forecast 2013 revenue of $19.5-$20.5 bln, adjusted EPS of $4.85-$5.15

* Expects 10 NTEs development next 2 years and may start generating sales in 2016

* Sees new therapeutic entities as multi-billion-dollar opportunity

* Prepared with aggressive launch of 3x week Copaxone if approved by FDA in 2014

 
We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (0)
Be the first to comment on reuters.com.
Add yours using the box above.